Loading...
XSES
T14
Market cap3.13bUSD
Jul 11, Last price  
2.43USD
1D
-1.22%
1Q
14.62%
Jan 2017
177.71%
IPO
604.35%
Name

Tianjin Zhongxin Phrmctl Gp Cp Ltd

Chart & Performance

D1W1MN
P/E
5.29
P/S
1.61
EPS
3.29
Div Yield, %
1.35%
Shrs. gr., 5y
—
Rev. gr., 5y
0.88%
Revenues
7.31b
-11.14%
2,517,141,0002,149,968,0002,258,414,0002,365,338,0002,880,863,2603,473,471,2664,391,889,1475,129,925,9876,010,136,7287,086,879,2787,080,552,2386,178,821,7965,689,242,4966,358,622,3186,993,881,6976,603,652,0156,907,544,2568,249,249,5658,222,311,8497,306,736,058
Net income
2.23b
+125.94%
80,787,000-377,764,000-72,819,000182,080,000257,817,625293,287,101247,649,856441,299,096351,794,374357,800,340451,442,939422,423,006476,079,838561,679,706625,568,681661,704,350769,144,377861,793,906986,707,3772,229,334,236
CFO
925m
+34.30%
261,906,000-28,083,00020,131,000155,768,00083,407,791139,035,377173,880,27720,808,888213,435,404286,854,209360,583,419419,901,9090350,144,366495,488,678671,420,832852,401,231677,245,078688,487,880924,672,004
Dividend
Jul 02, 20240.03272458 USD/sh

Profile

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and healthcare products primarily in the People's Republic of China. It operates in Chinese Medicine and Western Medicine segments. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; wholesale and retail sale of medicines, biochemical pharmaceutical products, and daily use products; and operation of hospitals. In addition, it provides logistics, stocks, equipment installation, and medicine processing services; medicine inspection and testing services; and pharmaceutical consultancy services. The company sells its medicinal products under its own brand to the wholesalers; and purchases medicinal products under other brands from distributors and sells these to other wholesalers. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was incorporated in 1992 and is based in Tianjin, the People's Republic of China.
URL
http://www.zhongxinp.com/
IPO date
Jun 06, 2001
Employees
4,913
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,306,736
-11.14%
8,222,312
-0.33%
8,249,250
19.42%
Cost of revenue
5,669,253
6,973,262
7,158,181
Unusual Expense (Income)
NOPBT
1,637,483
1,249,050
1,091,069
NOPBT Margin
22.41%
15.19%
13.23%
Operating Taxes
363,564
126,658
106,931
Tax Rate
22.20%
10.14%
9.80%
NOPAT
1,273,918
1,122,392
984,138
Net income
2,229,334
125.94%
986,707
14.49%
861,794
12.05%
Dividends
(859,149)
(386,722)
Dividend yield
3.31%
1.71%
Proceeds from repurchase of equity
(22,665)
BB yield
0.09%
Debt
Debt current
21,653
81,800
105,735
Long-term debt
11,206
246,520
153,042
Deferred revenue
55,139
2
59,876
Other long-term liabilities
34,071
100,831
50,729
Net debt
(2,911,574)
(2,699,860)
(3,439,310)
Cash flow
Cash from operating activities
924,672
688,488
677,245
CAPEX
(140,928)
Cash from investing activities
342,305
(744,213)
Cash from financing activities
(836,649)
FCF
1,471,089
928,660
1,610,162
Balance
Cash
2,944,433
2,145,507
2,882,524
Long term investments
2
882,673
815,564
Excess cash
2,579,096
2,617,065
3,285,626
Stockholders' equity
6,411,465
5,793,689
5,669,537
Invested Capital
5,387,307
4,454,581
3,437,984
ROIC
25.89%
28.44%
26.77%
ROCE
20.54%
17.64%
16.21%
EV
Common stock shares outstanding
768,873
770,865
776,391
Price
30.80
-8.47%
33.65
15.64%
29.10
-7.35%
Market cap
23,681,291
-8.71%
25,939,612
14.81%
22,592,975
-6.45%
EV
20,776,061
23,284,298
19,184,158
EBITDA
1,763,419
1,379,179
1,207,628
EV/EBITDA
11.78
16.88
15.89
Interest
40,195
35,853
10,269
Interest/NOPBT
2.45%
2.87%
0.94%